AU2018421487B2 - Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition - Google Patents

Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition Download PDF

Info

Publication number
AU2018421487B2
AU2018421487B2 AU2018421487A AU2018421487A AU2018421487B2 AU 2018421487 B2 AU2018421487 B2 AU 2018421487B2 AU 2018421487 A AU2018421487 A AU 2018421487A AU 2018421487 A AU2018421487 A AU 2018421487A AU 2018421487 B2 AU2018421487 B2 AU 2018421487B2
Authority
AU
Australia
Prior art keywords
formula
compound represented
crystal form
present application
maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018421487A
Other languages
English (en)
Other versions
AU2018421487A1 (en
Inventor
Jiawang GUO
Wubin PAN
Wei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Connect Biopharmaceuticals Ltd
Original Assignee
Suzhou Connect Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Connect Biopharmaceuticals Ltd filed Critical Suzhou Connect Biopharmaceuticals Ltd
Publication of AU2018421487A1 publication Critical patent/AU2018421487A1/en
Application granted granted Critical
Publication of AU2018421487B2 publication Critical patent/AU2018421487B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018421487A 2018-05-04 2018-05-04 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition Active AU2018421487B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Publications (2)

Publication Number Publication Date
AU2018421487A1 AU2018421487A1 (en) 2020-12-17
AU2018421487B2 true AU2018421487B2 (en) 2024-09-12

Family

ID=68387039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018421487A Active AU2018421487B2 (en) 2018-05-04 2018-05-04 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition

Country Status (13)

Country Link
US (3) US11512078B2 (enExample)
EP (2) EP4353719B1 (enExample)
JP (3) JP7275253B2 (enExample)
KR (2) KR102672632B1 (enExample)
AU (1) AU2018421487B2 (enExample)
CA (1) CA3099196A1 (enExample)
ES (1) ES2978392T3 (enExample)
IL (3) IL278464B2 (enExample)
MX (1) MX2020011665A (enExample)
NZ (1) NZ770323A (enExample)
SG (1) SG11202010969UA (enExample)
WO (1) WO2019210511A1 (enExample)
ZA (1) ZA202007347B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7275253B2 (ja) * 2018-05-04 2023-05-17 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
CA3201000A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
CN103450171B (zh) * 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
CN105315266B (zh) 2014-08-01 2019-10-01 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN115772166B (zh) * 2017-01-11 2025-01-03 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
JP7275253B2 (ja) * 2018-05-04 2023-05-17 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Also Published As

Publication number Publication date
US20250320200A1 (en) 2025-10-16
US12202822B2 (en) 2025-01-21
ES2978392T3 (es) 2024-09-11
IL312512A (en) 2024-07-01
IL278464A (enExample) 2021-03-01
IL312512B1 (en) 2025-11-01
CA3099196A1 (en) 2019-11-07
IL278464B1 (en) 2024-06-01
AU2018421487A1 (en) 2020-12-17
KR20240094023A (ko) 2024-06-24
EP4353719A1 (en) 2024-04-17
EP3792258A4 (en) 2021-10-06
JP7651198B2 (ja) 2025-03-26
JP2025074350A (ja) 2025-05-13
IL323665A (en) 2025-11-01
US11512078B2 (en) 2022-11-29
BR112020022429A2 (pt) 2021-02-09
EP4353719B1 (en) 2025-12-24
US20230050777A1 (en) 2023-02-16
JP7275253B2 (ja) 2023-05-17
US20210230152A1 (en) 2021-07-29
WO2019210511A1 (zh) 2019-11-07
IL312512B2 (en) 2026-03-01
NZ770323A (en) 2025-12-19
MX2020011665A (es) 2021-01-20
JP2023062091A (ja) 2023-05-02
EP3792258B1 (en) 2024-02-07
SG11202010969UA (en) 2020-12-30
KR102672632B1 (ko) 2024-06-07
EP3792258A1 (en) 2021-03-17
JP2021532165A (ja) 2021-11-25
KR20210019999A (ko) 2021-02-23
IL278464B2 (en) 2024-10-01
ZA202007347B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
US20250320200A1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
HUE026408T2 (en) Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN112778290B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
CN105461610B (zh) 一种阿普斯特的晶型及其制备方法、药物组合物和用途
TW201623294A (zh) １－｛２－氟－４－［５－（４－異丁基苯基）－１，２，４－噁二唑－３－基］－苄基｝－３－吖丁啶羧酸的晶型
CN106928228B (zh) 奥格列汀盐及其晶型、它们的制备方法和药物组合物
RU2822288C2 (ru) Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе
HK40106546B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40106546A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
JP2018510173A (ja) トピロキソスタットの新規結晶形及びその製造方法
HK40042284A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
BR112020022429B1 (pt) Forma cristalina do maleato de agonista de receptor s1p1, seu método de preparação, seu uso e composição farmacêutica que o compreende
BR122022025339B1 (pt) Sulfato de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1
BR122022025293B1 (pt) Sal de sódio de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)